Immunic price target raised to $13 from $10 at Brookline

Brookline raised the firm’s price target on Immunic to $13 from $10 and keeps a Buy rating on the shares. Following talks with management, the analyst is including sales projections for vidofludimus calcium for primary progressive multiple sclerosis, or ppMS, and non-reactive secondary progressive multiple sclerosis, or nrSPMS, in its model, the analyst tells investors.